John Maraganore
Co-Founder & Executive Chair,
City Therapeutics
John Maraganore is a co-founder and executive chair of City Therapeutics. He was the founding CEO and a director of Alnylam Pharmaceuticals - the leading RNAi therapeutics company - which he led for nearly 20 years from 2002-2021. Dr. Maraganore built and led Alnylam from early platform research on RNAi through global approval and commercialization of the first five RNAi medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, LEQVIO® and AMVUTTRA®. He led the company’s value creation strategy raising over $7.5B in capital, forming over 20 major pharmaceutical alliances and creating over $25B in market capitalization.
Prior to Alnylam, Dr. Maraganore held senior leadership roles at Millennium Pharmaceuticals, Inc. and at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc. and the Upjohn Company.
Dr. Maraganore is currently the CEO and principal of JMM Innovations, LLC, which is committed to the advancement of biomedical innovation to patients. He serves on the boards of Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics and Takeda Pharmaceuticals, in addition to several private company and non-profit boards. He is a member of the Biotechnology Innovation Organization board, where he was chair from 2017-2019. Dr. Maraganore received a M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago.
Suffix
PhD
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}